The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Betty Maillot; Guillaume Bouzille; Jean-Yves Mabrut; Edouard Girard; Alexis Laurent; Francis Navarro; Alexandre Chebaro; Laurence Chiche; Francois Faitot; Laurent Sulpice; Eric Vibert; Karim Boudjema

doi:10.12659/AOT.935892

08 March 2022 : Original article

The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Betty Maillot^1ABCDEF*, Guillaume Bouzille^2C, Jean-Yves Mabrut^3B, Edouard Girard

^4B, Alexis Laurent^5B, Francis Navarro^6B, Alexandre Chebaro

^7B, Laurence Chiche^8B, Francois Faitot

^9B, Laurent Sulpice^1AB, Eric Vibert^10B, Karim Boudjema^1ACDEF

DOI: 10.12659/AOT.935892

Ann Transplant 2022; 27:e935892

Authors information Article notes Copyright and License information

¹Department of Hepatobiliary and Digestive Surgery, CHU Rennes, Pontchaillou Hospital, University of Rennes 1, Rennes, France
²Department of Medical Information and Medical Records, CHU Rennes, Pontchaillou Hospital, University of Rennes, INSERM, LTSI-UMR 1099, Rennes, France
³Department of General Surgery and Liver Transplantation, Hôpital de la Croix-Rousse, University of Claude Bernard Lyon 1, Hospices Civils de Lyon. National Institute for Health and Medical Research (INSERM) Unit 1052/CNRS-5286, Lyon, France
⁴Department of Digestive Surgery and Emergency, CHU Grenoble Alpes, La Tronche Hospital, University of Grenoble Alpes, Grenoble, France
⁵Department of Digestive and Hepatobiliopancreatic Surgery, AP-HP, Henri Mondor Hospital, University of Paris-Est Créteil, Inserm, UMR-955, Paris, France
⁶Department of Hepatobiliary Digestive Surgery and Hepatic and Pancreatic Transplantation, CHU Montpellier, Saint Eloi Hospital, University of Medicine Montpellier-Nîmes, Montpellier, France
⁷Department of Digestive Surgery and Transplantation, CHU Lille, Huriez Hospital, University of Medicine Henri Warembourg, Lille, France
⁸Department of Hepatobiliary and Hepatic Transplantation, CHU Bordeaux, Haut-Lévêque Hospital, University of Bordeaux, Bordeaux, France
⁹Department of General, Hepatic, Endocrine and Transplantation Surgery, CHU Strasbourg, Hautepierre Hospital, University of Strasbourg, Strasbourg, France
¹⁰Hepato-Biliary Center, AP-HP, Paul Brousse Hospital, University of Paris-Saclay, Paris, France

^*Corresponding Author: Betty Maillot, e-mail: [email protected]
^*Corresponding Author: Guillaume Bouzille, e-mail: [email protected]
^*Corresponding Author: Jean-Yves Mabrut, e-mail: [email protected]
^*Corresponding Author: Edouard Girard, e-mail: rf.elbonerg-uhc@1drarige
^*Corresponding Author: Alexis Laurent, e-mail: [email protected]
^*Corresponding Author: Francis Navarro, e-mail: rf.reilleptnom-uhc@orravan-f
^*Corresponding Author: Alexandre Chebaro, e-mail: [email protected]
^*Corresponding Author: Laurence Chiche, e-mail: [email protected]
^*Corresponding Author: Francois Faitot, e-mail: [email protected]
^*Corresponding Author: Laurent Sulpice, e-mail: [email protected]
^*Corresponding Author: Eric Vibert, e-mail: [email protected]
^*Corresponding Author: Karim Boudjema, e-mail: [email protected]

^AStudy design/planning
^BData collection/entry
^CData analysis/statistics
^DData interpretation
^EPreparation of manuscript
^FLiterature analysis/search

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 7 Univariable and multivariable analysis of prognosis factors for patient survival after HT.

	Unadjusted HR [CI 95]	P unadjusted	Adjusted HR [CI 95]	P adjusted
HT	4.6 [2–11]	<0.001	4.2 [1.4–13]	0.01
Recipient age >48 years	2.5 [1–6.2]	0.042	2 [0.65–6.3]	0.22
ASAT >50 UI/L	0.34 [0.13–0.85]	0.023	0.62 [0.2–1.9]	0.40
ALAT >45 UI/L	0.37 [0.15–0.94]	0.037	0.38 [0.09–1.5]	0.16
PAL >200 UI/L	0.33 [0.11–0.95]	0.04	0.64 [0.16–2.5]	0.51
Creatinine >97.5 μmol/L	2.6 [1.3–5.4]	<0.01	1.3 [0.51–3.3]	0.58
Hb >10.9 g/dL	0.39 [0.18–0.85]	0.018	0.47 [0.13–1.7]	0.23
Donor age >61 years	2.4 [1.2–4.8]	0.018	2.8 [1.1–1.7]	0.02
Duration of cold ischemia >468 min	0.43 [0.2–0.9]	0.024	0.7 [0.26–1.9]	0.47
Surgery duration >402 min	2.8 [1.2–6.6]	0.023	2.8 [0.82–9.6]	0.10
Alcohol	0.46 [0.22–0.96]	0.037	0.38 [0.14–1]	0.06
Preoperative hepatorenal syndrome	2.5 [1–6]	0.039	3.2 [0.91–11]	0.07
HT – hemitransposition; OLT – orthotopic liver transplantation; HR – hazard ratio; CI – confidence interval; Hb – hemoglobin; RBCP – red blood cell pellet. Biological dosages correspond to preoperative data.

Back to the Article

The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Your Privacy